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Abstract
Modulatory cytokines such as IL-4 and IL-10 looked promising 
biologicals, but suffered from poor exposure at the inflamed joints 
when administered via the patient-friendly subcutaneous route. 
Immunocytokines have now been engineered with tissue targeting 
potential and are a possible solution to this problem, although 
challenges still exist. Local inflammatory processes cause destruc­
tion of extracellular matrix (ECM) components, leading to neo- 
eptitopes, and/or elicit the synthesis of new ECM components. 
This makes ECM elements interesting targets for antibody- 
mediated recognition and retention, to achieve higher levels of 
immunocytokines at the site of therapeutic interference. The study 
presented by Schwager and colleagues shows that targeted 
delivery of IL-10 is more efficacious in experimental arthritis. 
Clinical studies are warranted to show whether this strategy works 
for all rheumatoid arthritis patients or is better for subgroups with a 
defined ECM phenotype. In principle, the scFv-targeting system is 
plastic enough to allow for personalized strategies.
Immunocytokines
The successful introduction of biologicals such as neutralizing 
anti-TNF-antibodies in the treatment of rheumatoid arthritis has 
paved the way for using immunocytokines in non-lethal 
diseases. The study of Kathrin Schwager and colleagues [1] in 
a recent issue of Arthritis Research & Therapy reports 
impressive preclinical results using F8-IL-10 (DEKAVIL), a fully 
human fusion protein of the single-chain Fv (scFv) antibody 
F8, which specifically recognizes the extra-domain A  (EDA) of 
fibronectin, w ith the anti-inflammatory cytokine IL-10. They 
showed the accumulation of this fusion protein at the site of 
inflammation, good therapeutic efficacy and a safety profile 
that provides the basis for the first clinical trial of antibody- 
based pharmacodelivery of DEKAVIL in rheumatoid arthritis 
(RA) patients
In general, immunocytokines are scFv fragm ents of a m ono­
clonal antibody directed against a specific  target fused to a 
cytokine, thus retaining the functions of both the antibody and 
the cytokine. In cancer, the use of single-chain antibody 
fragm ents for targeting and in v ivo  imaging of tumors is a new 
weapon in the oncolog ist's  armamentarium [2]. These scFvs 
show  good tum or targeting and biodistribution properties 
w ith a tum or-to-background ratio of more than 10%  ID/g.
Extracellular matrix components for retention 
of immunocytokines
The therapeutic potential of recombinant cytokines is often 
limited by severe toxicities due to the high dosages needed 
as cytokines often have poor pharmacokinetics and dynamics. 
A  straightforward strategy is the fusion of cytokines w ith the 
Fc tail of antibodies or liposomal encapsulation to increase 
the ir half-life in the circulation, although this will not improve 
the local accumulation [3,4]. Schw ager and colleagues [1] 
showed that cytokines can be targeted to the site of interest 
by using scFv antibody fragm ents recognizing extracellular 
matrix (ECM) com ponents present in the joint. The first 
question they addressed is which ECM  protein is the best 
targetable candidate in the inflamed joint. Their approach was 
a side-by-side comparison of im munohistochemical staining 
of synovial tissue of several antibodies directed against 
d ifferent ECM  antigens, and identified EDA, a splice variant of 
fibronectin, as the best candidate. They showed a therapeutic 
e ffect of F8-IL-10 that was better than an IL-10 fusion protein 
directed against an irrelevant protein antigen.
Concomitant neutralization of signaling?
Unfortunately, they did not include in their studies the 
therapeutic impact of the targeting antibody alone, w ithout
ECM =  extracellular matrix; EDA =  extra-domain A; IL =  interleukin; RA =  rheumatoid arthritis; scFv =  single-chain Fv antibody fragment; TLR =  Toll­
like receptor; TNF =  tumor necrosis factor.
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IL-10, or coupled to an inactive protein. It is now well 
accepted that EDA is an endogenous Toll-like receptor 4 
(TLR4) ligand [5], and the F8 scFv antibody fragment 
possibly interferes w ith EDA-induced TLR4 signaling by 
blocking or steric hindrance. W e recently dem onstrated an 
important role for TLR4 in experimental arthritis. Blocking 
TLR4 using Bartonella lipopolysaccharide, a naturally 
occurring TLR4 antagonist, clearly ameliorates murine 
collagen-induced arthritis [6]. This potential double hit may 
add another layer of activity to the immunocytokines. The 
possib ilities are unlim ited as recombinant antibody fragm ents 
can be engineered to assemble into stable multimeric 
oligom ers of high binding avidity and specific ity to a w ide 
range of target antigens and haptens [7]. M ulti-specific Fv 
m odules can be designed as cross-linking reagents for local 
accum ulation of cytokine action through attachm ent to the 
ECM and by targeting carrier cells or proteins fo r trafficking 
to the joint. Furthermore, it is possible to select human svFc 
m onoclonal autoantibodies for ECM proteins from B-cell 
phage-display libraries derived from RA patients that are 
more specific  (recognizing RA-specific neo-epitopes as 
citrullinated antigens) and have higher affinities [8]. As well as 
the ECM, other proteins that are extremely upregulated and 
pro-arthritic in the inflamed jo int (for example, S 10 0  alarmins) 
are candidate targets fo r scFv antibody-based im m unocyto­
kines [9].
Local delivery versus local accumulation?
Intra-articular therapy is attractive in RA patients to enhance 
efficacy of a drug and reduce side-effects associated with 
systemic immunosuppression. Rheumatologists are familiar 
w ith local injections - for example, to extinguish the inflamma­
tion in affected joints w ith corticosteroids. Results from local 
delivery of anti-TNF biologicals are encouraging, and although 
a plausible form of therapy, larger studies are warranted to 
address the safety issues associated with repeated and 
prolonged antibody delivery in the joint [10]. The gene-therapy 
field has acknow ledged this strategy and used recombinant 
vectors to transduce the synovium and produce biologicals 
locally. However, even using local gene delivery, effects on 
ipsilateral and contralateral jo ints were reported, although it 
remains debatable whether this reflected spill-over of 
biologicals to the system [11]. Com bining the best of both 
strategies - local synthesis and retention using scFv antibodies 
against ECM com ponents - can be envisioned.
Perspective
The successful in troduction of immunocytokines as a magic 
bullet in the treatm ent of RA will depend on the spontaneous 
generation of autoantibodies against the svFc part of the 
molecule. The presence of anti-id iotypic antibodies has been 
identified in sera of RA patients, and these antibodies may 
impair the accumulation of immunocytokines, neutralize the 
cytokine activity and prohibit repeated injection. So far, au to­
antibodies against fully humanized anti-TNF antibodies have 
not been a major problem and we are hopeful that
immunocytokines will become a therapeutic reality in RA
patients in the near future.
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